nature.com/articles/s41587-0…
The first FDA approved clinical trial testing rejuvenation with partial cellular reprogramming factors is about to start!
This is a huge moment for the longevity field.
Partial cellular reprogramming has the potential to not just slow biological aging, but reverse aspects of age-related decline. This is not theory; it has been shown in preclinical studies, including data from Life Bioscience's founder, David Sinclair's lab, demonstrating restoration of vision in partially blind mice.
This 5 year clinical trial will test whether pulsed delivery of three cellular reprogramming factors (O, S, K) can restore vision in individuals with forms of optic neuropathy and glaucoma -- common drivers of vision loss.
Keep in mind, this technology relies on a form of gene therapy: cost, scalability, and accessibility are major bottlenecks. Long-term safety in humans is still a major outstanding question. The time horizon for this particular technology to reach the masses (if it succeeds in restoring vision) is 1-2 decades at a minimum. A small price to pay for the potential massive impact of rejuvenation.
Even more reason for optimism.
@OMIPALRLL and
@ReprogLab are working hard in parallel to develop and validate chemical reprogramming factors that capture the rejuvenative impact with small molecules, peptides, familiar factors that can greatly reduce cost, improve safety profile, and accelerate time to market and accessibility.
Not just for restoring vision -- but age-related diseases that impact the brain, immune system, heart, and muscles. Potentially even prevention.
2026 has started with a breakneck pace, and the future of longevity is bright!
The fundamental strategy of today:
1) Track and support labs/companies driving the breakthrough science
2) Stay healthy enough for long enough to engage with the rejuvenative technologies already in the pipeline.